$MXCT #Maxcyte Inc MaxCyte: Milestones a key contributor to 30% top line growth: MaxCyte delivered a consensus-beating 30% uplift in full-year 2019 (FY19) revenues to US$21.6mln underpinned by the release of milestone payments from its… https://t.co/1X59JGA39l #equity #stocks https://t.co/Z2OWfqWl6e